affected as the tumor progresses because their seizure activity often increases in frequency and severity. 11 In addition, central nervous system (CNS) metastasis is also a major concern to a number of primary cancers. The number of cases of each primary cancer type that may manifest CNS metastasis can vary. 12 Symptomatically, many of these patients with CNS metastasis may experience seizure episodes and need long-term anticonvulsant therapy. The efficacy of AEDs in the treatment of epilepsy is well-established, 13, 14 and the prophylactic use of anticonvulsant therapy is common practice for clinicians treating patients with brain tumors, 15 regardless whether these patients have had episodes of seizures in the past, presumably based on personal preference, training and experience, despite a lack of clinically available evidence on its efficacy. The liability issue of being ''sensitive'' to any untoward results of the patient, such as seizures, leading to unnecessary legal action by family members may also bias this practice. 16 Thus, it is important for clinicians to make accurate, timely, safe and effective decisions with regards to drug use in the patient. They must be vigilant when prescribing other concomitant medications with anticancer agents so as to prevent unwanted toxicities and inadequate drug exposures due to DDIs. There are three scenarios in which DDIs can potentially affect the therapy for cancer patients: (a) addition of an interacting drug to a patient's existing chemotherapy treatment, (b) giving chemotherapy treatment to a patient who is concurrently on an interacting drug, and (c) removal of an interacting drug from a patient's chronic chemotherapy. Pharmacokinetic and/or pharmacodynamic interactions can result, leading to clinically significant toxicities or therapeutic failures. 7 By knowing the magnitude of the DDIs, clinicians can better manage their patients' drug therapies. Information technology (IT) has gained increasing acceptance among healthcare professionals in their clinical practice. The application of cancer informatics has enabled healthcare professionals to keep themselves updated in the latest developments in oncology, and also proper therapeutic management strategies through the use of online databases and software tools. 17 Drug information databases which provide relevant DDI information on ACD therapies can potentially improve pharmaceutical care in cancer patients and improve their quality of life. Although there are more than 2000 drug interactions that have been identified, only a limited number are of interest from a clinical standpoint. 18 The challenge is for the healthcare professional to critically evaluate the vast amounts of available information so as to provide the best care for the patient's well-being. Multiple online databases are available as drug information resources to healthcare professionals, such as the American Hospital Formulary Service (AHFS) Drug Information, 19 British National Formulary (BNF), 20 Lexi-Comp Online 21 and Micromedex
Healthcare Series. 22 However, currently no drug interaction database is dedicated to allow the search of ACD interactions by chemotherapy regimens. Most of the currently available drug interaction databases require the input of individual drugs in a patient's prescription in order to search for drug interactions. Thus, the objective of this project is to provide clinicians dealing with cancer patients with an oncology-specific drug interaction database that is relevant to their daily practice. This database will focus on DDIs with ACDs, single-and multiple-agent chemotherapy regimens.
Materials and methods
The development of OncoRx involves three main steps: (a) the compilation of information on drugs, chemotherapy regimens and drug interactions from published literature sources, (b) the creation of the database and graphical user interface, and (c) the mounting of the database onto the server. A summary illustrating the process of developing OncoRx is shown in Fig. 1 . 29 and product information of the various drugs. In addition, chemotherapy regimens that are positively evaluated in Phase II or III trials and published in English-language journals, or regimens which are approved by the US FDA, were collated from PubMed using the keywords ''chemotherapy regimens'', ''anticancer drugs'' and the generic names of the ACDs. These regimens included both single-and multiple-agent combinations. Each individual drug used in the chemotherapy regimen was then listed out so that its interaction with AEDs could be compiled. In each case, references in scientific literature describing the regimen would also be collated. However, since the treatment combinations can vary among different institutions in terms of doses and frequencies of administration, these parameters were not included in our database. Drug-related information compiled included the generic names and indexed terms of the drugs, their pharmacological categories, mechanisms of action, percentages of bound protein, metabolism and elimination routes, and enzymatic parameters; while chemotherapy-related information included the acronyms of the chemotherapy regimens, the drugs used in the regimen, the types of cancer they treat, and references substantiating the use of the regimens in cancer treatment.
On the other hand, drug interaction information consisted of the interaction effects, interaction mechanisms, substantiating evidences, proposed management plans, and references. These information were compiled from the resources previously mentioned, as well as documented literature from PubMed based on the keywords 'anticancer', 'antiepileptic', 'chemotherapy regimen', 'drug interactions', and the generic names of the individual ACDs and AEDs. When the DDI documented in the various resources was found to be different, this information would be collated together with the appropriate substantiating evidence and reference citations.
Creation of the database and graphical user interface
The data collected was distributed into interrelated tables in Microsoft Excel. The program structure of the search interface was designed around the generic names of the ACDs, as well as combination chemotherapy regimens. A Structured Query Language (SQL), known as MySQL, was then used to create tables and store data information in a MySQL 5.0 database based on the structure of the excel tables. Documents were created using the Adobe Dreamweaver CS4 software, and were associated with a combination of hypertext markup languages (HTML) and javascripts. Cascading style sheets (CSS) were used in the designing of the web documents so as to provide a consistent look for the whole website.
Mounting of the database onto the server
The OncoRx database was programmed with a server-side scripting language known as hypertext preprocessor (PHP 5) running as a common gateway interface (CGI) application. A domain was bought from the DreamHost TM web hosting company, 30 which used an Apache 2.0 web server installed on a Debian
Linux server. An open source tool written in PHP, known as phpMyAdmin 2.11.2.1, was used to handle MySQL administration over the web. PHP is a scripting language designed to be embedded in HTML, and a CGI enables the client web browser to request data from the web server. Database queries were handled through SQL access to the database, and the contents of the database were returned to the client's browser. The choice of scripting language is somewhat arbitrary with other languages such as Active Server Pages (ASP) and Perl being the more popular ones. However, PHP is gaining recognition due to its ease of implementation, thus it was used in this project.
Results

OncoRx-a database for detecting drug interactions with chemotherapy regimens
OncoRx is an online oncology database whose structure is designed around chemotherapy regimens and generic drug names used in anticancer treatment. The database can be accessed at the web link www.onco-informatics.com. The first module concentrates on interactions of single-and multiple-agent chemotherapy regimens with AEDs. Users can search for a drug interaction from 2 search interfaces-using either generic drug names of the ACDs or chemotherapy combination regimens (Fig. 2) .
The OncoRx database currently consists of 117 ACDs which make up 256 single-agent and combination chemotherapy regimens, and can detect up to over 2000 interactions with 24 AEDs. The database covers all the major classes of ACDs and their frequently prescribed chemotherapy combination regimens used in the treatment of cancer patients. It focuses primarily on pharmacokinetic-related DDIs since majority of the interactions are known to involve the induction and/or inhibition of hepatic cytochrome P450 (CYP450) metabolism. The AEDs in the database include the commonly used older generation drugs such as carbamazepine, phenytoin, phenobarbital, primidone and valproic acid, as well as the newer generation drugs like gabapentin, lamotrigine and levetiracetam.
Search strategy for interactions using generic anticancer drug names
Users can search for a DDI by the generic name of the ACD, for example between doxorubicin and valproic acid, using the scrolldown menu as shown in Fig. 3 . The relevant data will be extracted from the database and the results displayed for the user. The information is presented in tabular format and consists of three parts: the pharmacokinetic parameters of the ACD and AED, and parameters of the detected DDI.
The generic names of the user choice of ACD and AED are displayed at the top of the results page, together with other indexed terms of the drugs. Pharmacokinetic data include the absorption, protein-binding information, metabolism and elimination routes of the drugs, as well as enzymatic parameters such as substrate, inducer and/or inhibitor information. In addition, the pharmacological category of the ACD, its indication in cancer therapy, and mechanism of action are also shown to users. The last section of the results page provides the interaction effects, mechanism and a summary of the studies that substantiate the DDI, together with a proposed management plan for the DDI. In the given example, a decrease in plasma valproic acid levels is expected, which may lead to decreased effectiveness of the AED and possible loss of seizure control. 31 The clinician should monitor the patient for seizure control when using these two drugs concurrently, or consider an alternative antiepileptic. Other AEDs in which an interaction with the ACD is not identified are listed as well.
Search strategy for interactions using the acronyms of chemotherapy regimens
Clinicians can also search for interactions of a combination chemotherapy regimen with an AED based on the acronym of the regimen, such as EP and phenytoin (Fig. 4) . EP is a combination chemotherapy regimen consisting of etoposide and cisplatin, and used for the treatment of small-cell lung cancer. 32 As shown in the results, this time, in addition to the pharmacokinetics of each ACD in the regimen and the AED, information on the chemotherapy regimen will be shown. These include the types of cancers which it is indicated for, the drugs in the regimen, as well as relevant substantiating references. The management plan proposed for the detected DDI, however, is now for the combination regimen instead of the individual ACDs. With regards to EP, the results caution the clinician to monitor for adequate patient response to etoposide, plasma phenytoin levels, as well as seizure control.
Other features of OncoRx
This database caters towards health professionals who specialize in oncology and neurology, as well as those in general disciplines who encounter cancer patients in their daily practice. Besides enabling DDI searches based on chemotherapy regimen acronyms, an additional feature was also incorporated so that clinicians can search for DDIs of chemotherapy regimens based on various types of cancers. This makes it easier for clinicians to search for a particular regimen if they know the type of cancer which the patient is suffering from. Currently, the regimens in OncoRx have been classified into 16 categories which range from bone and tissue cancers to HIV-related cancers and pediatric regimens (Fig. 5 ). Akin to other medical disciplines, oncology practitioners have their own clinical specializations. For example, an oncologist can specialize in treating breast and gynecologic cancers, while another's expertise may lie in the treatment of gastrointestinal and colorectal cancers. In such cases, users can search for DDIs of specific chemotherapy regimens based on the type of tumors or malignancies which they treat. Needless to say, cancers affecting the CNS and brain would be of great relevance to neuro-oncologists. On the other hand, this database also offers an advantage to clinicians in neurology practice who may not be familiar with the ACDs in combination chemotherapy regimens. In such cases, clinicians can search based on the acronym of the regimen, and even narrow their regimen searches based on the type of cancer treated, and OncoRx will be able to provide the clinician with any identified drug interactions with the drugs in the regimen.
Another feature is the inclusion of a feedback form which seeks users' comments on how the OncoRx database can be improved. This form serves as an important component for OncoRx as it would determine the usefulness of this database in clinical practice, and also its target audience. The feedback obtained will then allow us to constantly update the database with features and DDI information that are clinically relevant to practicing clinicians.
Discussion
Translating bench to bedside with cancer informatics-OncoRx is the bridge
Translational research has been an area of discussion within the scientific community in recent years. The Translational Research Working Group (TRWG) at the National Cancer Institute (NCI) relates translational research to scientific discoveries from laboratory, clinical or population studies which lead to clinical applications that can reduce cancer incidence, morbidity and mortality. 33 However, it is more commonly understood as the application of science that ''translates'' discoveries from the laboratory bench to the patient's bedside or from mouse to man. 34 The integration of healthcare with informatics and interactive technologies has enabled computational tools to play an important role in the management of clinical knowledge and information, particularly in oncology. However, there is a further need to link basic biomolecular research to the clinical sciences with more effective informatics and protocol management. Medical informatics is a basic biomedical science that draws on both the informatics and health services arenas to develop studies and instruments to solve clinical issues in the practical setting. 35 Inherently, medical informatics has two main objectives: to search for new knowledge, and to utilize this knowledge in application research so as to improve healthcare practice. 36 Cancer informatics is a branch of medical informatics which applies informatics, internet and interactive technologies to the oncology domain; and can provide a bidirectional interplay between laboratory research and clinical practice. 37 Data on new anticancer agents (e.g. targeted therapies) and combination regimens flow from academic and industrial research to the clinical setting for therapeutic management of the disease, while patient-oriented research provides ideas and biological data for the laboratory to search for newer targets for drug discovery and development. The development of OncoRx can be visualized as a bridge which links drug interaction studies done in vitro or in animal models (bench) to clinical practice (bedside). Pharmaceutical care in cancer patients can be improved through the use of this database, since it can potentially minimize the occurrence of drugrelated problems such as drug interactions.
Antiepileptic drugs as the first module in OncoRx
Drug interactions due to AEDs are extremely common in clinical practice. An estimated 6% of patients with AED intoxication are due to drug interactions. 38 This is because the probability of a coprescription in patients on AED therapy is high since AEDs are often administered chronically, possibly over a lifetime. Patients who are treated with certain types of anticancer agents, for example busulfan, 39 are prone to generalized seizures and seizure prophylaxes are often warranted in these patients. 39, 40 High-dose busulfan may lead to neurotoxicity in the patient since it crosses the blood-brain barrier rapidly with a cerebrospinal fluid to plasma ratio of 1:1, 40 and it is estimated that the occurrence of seizures in adults and children on high-dose busulfan is 10% and 7.5% respectively. 40 It is known that phenytoin is an effective anticonvulsant used for this purpose, but it is associated with altering the pharmacokinetics, and possibly the pharmacodynamics, of busulfan as well. 41 Thus, the first module of OncoRx focused on DDIs of ACDs and combination chemotherapy regimens with anticonvulsants, which in essence, limits the database to only being able to detect interactions with 1 class of psychotropic drugs. However, this was done so as to cater towards clinicians who prescribe this class of drugs, so that they can treat the patient more effectively by avoiding inadequate drug levels or potential doserelated toxicities.
Potential of the OncoRx database in clinical practice
Currently, there is no oncology-specific database which allows healthcare professionals to search for interactions by both individual ACDs and combination chemotherapy regimens. Although some databases such as OncoLink, 42 Adjuvant Online, 43 and the BC Cancer Agency (BCCA) cancer drug manual 26 provide useful information on ACDs and cancer therapies, they do not specifically target chemotherapy drug interactions. OncoRx caters towards a niche group of healthcare professionals working in the clinical oncology or neurology setting, who may deal with cancer patients on chemotherapy in their daily practice. The main advantage of OncoRx is its ease of use for practitioners to search for chemotherapy drug interactions ''on-the-spot'', as and when they encounter them. As far as we know, there is currently no drug interaction database which allows users to search for drug interactions via combination chemotherapy regimens. OncoRx is the first database of its kind which targets the DDIs of chemotherapy regimens. This database saves time and effort on the part of healthcare professionals as they do not need to search for interactions of the individual drugs in a combination regimen (since they are standard within the regimen), but rather through their acronyms. Furthermore, OncoRx provides a proposed plan for managing the combination chemotherapy regimen if a drug interaction is detected. This makes it easier for the management of the patient since the healthcare professional can get the overall view of the interactions in the regimen, instead of collating and extracting relevant information for each individual drug interaction himself. The content in the OncoRx database is summarized and placed under relevant headings so that the health professional can rapidly sieve out the relevant information they need. Although several drug information databases provide detailed information about an interaction, it is a time consuming process for the clinician since it requires a thorough read of the details in order to sieve out the relevant information in the practice setting. On the other hand, other databases only provide a summarized paragraph of the detected drug interaction, mainly on the interaction effects and precautions to take. Users may have to search other information resources for more details on the interactions.
Some resources do not provide interactions of individual drugs, but of drug classes or drugs with certain common parameters instead. This requires some specialized knowledge on the part of the healthcare professional regarding the drug, and may be time consuming if he needs to look up additional information in the practice setting. For example, the increased risk of carboplatin toxicity when used concomitantly with nephrotoxic drugs 24 implies that the clinician needs to know whether the interacting drug is nephrotoxic, or otherwise look up for this piece of information on the interacting drug. OncoRx enables its users to search for interactions between specific drug-pairs, since it extrapolates these class effects to the individual drugs. Lastly, OncoRx compiles drug interaction information from various drug information and interactions sources, as well as other published literature. This makes the database a comprehensive one. As a result, OncoRx is also able to provide the clinician with any contradictory information regarding a detected drug interaction. For example, corticosteroids such as dexamethasone which are commonly used as antiemetic agents in treating chemotherapy-induced nausea and vomiting, 44 have been reported to cause both increases and decreases in plasma phenytoin levels. The OncoRx database is able to provide this piece of information as a summary of the evidence with substantiating references (Fig. 6) , so that the healthcare professional has the flexibility of deciding how to manage the patient based on his clinical judgment.
Limitations and future work
The main limitation of OncoRx is that it is currently only able to provide DDI information between ACDs and AEDs. However, the interaction data in our database is compiled in modular format, and further modules on DDIs with other psychotropic drugs and agents which have high potential of manifesting interactions with ACDs will be considered. OncoRx is also currently limited to searching for only one interaction at any one time. Separate searches have to be carried out when detecting more than one interaction and this can be troublesome for the user. Improvements in the search interface will also be considered as more modules are being added to the database. Moreover, with the advent of mobile handheld devices, the potential of incorporating our database into personal digital assistants (PDAs) is also attractive. OncoRx is intended to be updated regularly on an annual basis so that the DDI-related information regarding ACDs and chemotherapy regimens will remain current.
Conclusions
OncoRx is an oncology drug interaction database which allows the identification of DDIs between anticancer agents and adjuvant drug therapy, and can be accessed at the website www.oncoinformatics.com. This database was developed as part of a doctoral research project by a registered pharmacist in Singapore dualtrained in the pharmaceutical sciences and in digital media creation; in consultation with professors at the Department of Pharmacy, Faculty of Science, National University of Singapore; of whom one of them is US board-certified as both a pharmacotherapy specialist and an oncology pharmacist, with a concurrent appointment at the pharmacy department in the National Cancer Center, Singapore. OncoRx is the first database of its kind to be able to detect interactions for combination chemotherapy regimens. This database comprises relevant information related to the pharmacokinetic properties of the anticancer agents, as well as the drug interactions with other medications, such as anticonvulsants. OncoRx is meant to complement the currently available drug databases used by clinicians to improve the pharmaceutical care of cancer patients. By increasing the awareness of oncology drug interactions among healthcare professionals and other researchers in this field, we hope that our database will provide the bridge in cancer informatics to bring oncology drug interactions from bench to bedside. 6 . Screenshots of the interaction results between dexamethasone and phenytoin. A summary of evidences describing the inconsistency in the interaction effect of dexamethasone on plasma phenytoin levels is provided together with substantiating references to clinicians.
